Centre of Research Excellence in Pulmonary Fibrosis
PACT PF Australasian Clinical Trials

GRIPF Study

Trial title	Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF)
Trial synopsis	We are seeking suitable participants for a research study that examines how genetic factors may contribute to Idiopathic Pulmonary Fibrosis (IPF), a rare but severe lung disease. We are interested in involving families in this study as this will allow us to look at genetic similarities and differences in family members with and without disease. This national research project is being carried out by a team of researchers from the Menzies Institute for Medical Research, University of Tasmania in collaboration with the Australian IPF Registry. Both the Registry and this study are facilitated by Lung Foundation Australia. This study plans to learn more about pulmonary fibrosis and determine if genetic factors contribute to the development of diseases which result in scarring in the lung. What we learn may be helpful in the future to people diagnosed with these diseases, known as pulmonary fibrosis, and their family members.
Investigational medicinal product, comparator and randomisation	N/A
Disease target	IPF
Sponsor	Philanthropic support
Duration	Ongoing recruitment- 5 years
Trial Status	Recruiting
Trial phase	N/A
Key inclusion criteria	Families will have at least one member with IPF and other members impacted by pulmonary fibrosis.
Key exclusion criteria	N/A
Number of participants sought	20 well described families, family members with and without disease.
Lead site(s) in Australia	Royal Prince Alfred Hospital (NSW)
Lead site(s) in New Zealand	N/A

Additional sites	• The Alfred Hospital (VIC) • John Hunter Hospital (NSW) • Royal Adelaide Hospital (SA) • The Prince Charles Hospital (QLD)
Contact	enquiries@pactnetwork.com.au